Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology
An erratum to this article was published (J Am Coll Cardiol, 11 Aug 2026 ↗)
Scope
As issued by the authors
Overview of gene editing therapies in CVD for the practicing clinician: basic science, diseases most amenable to initial application (certain variants of hypercholesterolemia and amyloidosis), and inherent challenges incl. societal and ethical implications of high-cost, single-treatment cures
Original publication
Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. Published 26 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →